Correction: Targeted doxorubicin delivery to hepatocarcinoma cells by lactobionic acid-modified laponite nanodisks

Key Points

• Targeted delivery of doxorubicin improves therapeutic outcomes in hepatocarcinoma cells, enhancing effectiveness.
• The use of lactobionic acid-modified laponite nanodisks increases the precision of drug delivery to cancer cells.
• Laponite nanodisks serve as a promising platform for drug delivery applications, especially in targeted therapies.
• This approach may lead to reduced side effects and increased efficacy in treating liver cancer.